Drugs / JH020002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06139575 | Dec 2023 → May 2026 overdue | prostate cancer | Bivision Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JH020002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06139575 ↗ |